

**CLAIMS PENDING AFTER AMENDMENT**

1           32. A compound having a structure selected from:

2            $X-R-A-Q-(Y)_n$ ,  $R-X-A-(Y)_n-Q$ ,  $R-X-A-Q-(Y)_n$ , and

3            $X-R-A-(Y)_n-Q$

4           wherein,

5           A is a nucleic acid chain comprising nucleic acid monomers selected from the group  
6           consisting of natural nucleic acids, modified nucleic acids and combinations thereof;

7           R is a molecular energy transfer donor;

8           Q is a molecular energy acceptor; and

9           X and Y are the same or different and are non-nucleic acid stabilizing moieties that  
10          interact to bring R and Q into operative proximity, thereby enabling transfer of energy from R to Q;  
11          and

12          n is 0 or 1.

1           33. The compound according to claim 32, wherein said molecular energy donor is  
2          a fluorophore.

1           34. The compound according to claim 32, wherein said molecular energy acceptor  
2          is a fluorescence quencher.

1           35. The compound according to claim 32, wherein X and Y are both hydrophobic  
2          moieties.

1           36. The compound according to claim 35, wherein X and Y are members  
2          independently selected from the group consisting of saturated hydrocarbons, unsaturated  
3          hydrocarbons, steroids, fatty acids, fatty alcohols and hydrophobic peptides.

1           37. The compound according to claim 32, wherein natural nucleic acids are  
2          members selected from the group consisting of deoxyribonucleotides, ribonucleotides and  
3          combinations thereof.

1           38. The compound according to claim 37, wherein said modified nucleic acids  
2 are peptide nucleic acids.

1           39. The compound according to claim 32, wherein said nucleic acid monomers  
2 are joined by linkages that are members independently selected from the group consisting  
3 of phosphodiesters and modified phosphodiesters.

1           20. The compound according to claim 39, wherein said modified phosphodiesters  
2 are members selected from the group consisting of phosphorothioates and phosphoramidates.

1           41. The compound according to claim 32, wherein said nucleic acid sequence  
2 further comprises a hybridization enhancing moiety.

1           42. The compound according to claim 41, wherein said hybridization enhancing  
2 moiety is a member selected from the group consisting of intercalating agents, minor groove binders  
3 and modified exocyclic bases.

1           43. The compound according to claim 32, wherein X and Y are independently  
2 attached to members selected from the group consisting of a natural base of said nucleic acid chain, a  
3 modified base of said nucleic acid chain, a 3'-hydroxyl group of said nucleic acid chain, a 5'-  
4 hydroxyl group of said nucleic acid chain, a 2'-hydroxyl group of said nucleic acid chain, and a  
5 linkage joining nucleic acid groups in said nucleic acid chain.

1           44. The compound according to claim 32, wherein said compound is immobilized  
2 on a solid surface.

1           45. A method for amplifying a polynucleotide, wherein a compound according to  
2 claim 32 is a primer in said method, said method comprising:

3           (a) hybridizing said primer to said polynucleotide; and  
4           (b) amplifying said polynucleotide.

1           46. The method according to claim 45, wherein said amplifying is a member  
2 selected from the group consisting of polymerase chain reaction (PCR), nucleic acid sequence based  
3 amplification (NASBA), strand displacement amplification (SDA) and combinations thereof.


1           47. A method for detecting or quantitating a nucleic acid, wherein the compound  
2 according to claim 32 is used as a probe, said method comprising:

3                 (a) hybridizing said compound to said nucleic acid; and  
4                 (b) detecting a change in fluorescence of said compound, thereby detecting or  
5 quantitating said nucleic acid.

1           48. The method according to claim 47, wherein said method comprises a member  
2 selected from the group consisting of 5'-nuclease assay, rolling circle amplification and  
3 combinations thereof.

1           49. A kit for quantitating nucleic acid, said kit comprising a compound according  
2 to claim 32.

1           50. A compound having the formula:



5           wherein,

6           CHOL is a cholesterol derivative;

7           R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are linker moieties independently selected from the group  
8 consisting of substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;

9           Nu<sup>1</sup> and Nu<sup>2</sup> are members independently selected from the group consisting of  
nucleotide residues and nucleoside residues;


10          NA is a nucleic acid sequence;

11          D is a donor of light energy; and

12          Q is a quencher of light energy,

13          wherein each CHOL interacts with the other CHOL to bring D and Q into operative  
14 proximity, thereby enabling transfer of energy from D to Q.

1       51. The compound according to claim 50, wherein R<sup>1</sup> and R<sup>2</sup> are independently  
2 selected and have structures according to the formula:



5 wherein,

6       R<sup>11</sup> is a member selected from the group consisting of substituted or unsubstituted  
7 alkyl and substituted or unsubstituted heteroalkyl;

8       PEG is polyethylene glycol;


9       Y<sup>3</sup> is an organic functional group adjoining said PEG to said CHOL.

1       52. The compound according to claim 51, wherein said PEG has from about 2 to  
2 about 20 ethylene glycol subunits.

1       53. The compound according to claim 51 in which R<sup>11</sup> is substituted or  
2 unsubstituted alkyl.


1       54. The compound according to claim 53, wherein R<sup>11</sup> is C<sub>1</sub>-C<sub>6</sub> substituted or  
2 unsubstituted alkyl.

1       55. The compound according to claim 51, wherein Y<sup>3</sup>-CHOL has the structure:




1       56. The compound according to claim 50, wherein Nu<sup>1</sup> and Nu<sup>2</sup> are nucleotides  
2 having an exocyclic amine group to which -R<sup>1</sup>-D and -R<sup>4</sup>Q are attached, respectively.

1           57. A compound having the structure:



1           61. The compound according to claim 57, wherein Y<sup>1</sup>-CHOL and Y<sup>2</sup>-CHOL have  
2 the structure:



1           62. The compound according to claim 57, wherein Nu<sup>1</sup> and Nu<sup>2</sup> are nucleotides  
2 having an exocyclic amine group to which -R<sup>5</sup>-D and -R<sup>6</sup>-Q are attached, respectively.